Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 21 Sept 2026

Ki-67 Grade and Lu-177 DOTATATE Eligibility in GEP-NET

Your Ki-67 grade is one of the first numbers a PRRT team reviews when you have a GEP-NET. This article explains what each grade means for Lu-177 DOTATATE eligibility - and what to do if your case falls in a gray zone.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 21 Sept 2026
Ki-67 Grade and Lu-177 DOTATATE Eligibility in GEP-NET

Ki-67 Grade and Lu-177 DOTATATE Eligibility in GEP-NET

If you have a gastroenteropancreatic neuroendocrine tumor (GEP-NET) - a tumor in the stomach, intestines, or pancreas - you have probably seen a number called Ki-67 on your pathology report. That number affects more treatment decisions than almost any other test result. When a nuclear-medicine team asks whether you are a candidate for lutetium Lu-177 dotatate (brand name: Lutathera), this number is one of the first things they review. Lu-177 DOTATATE is also called peptide receptor radionuclide therapy (PRRT), a type of targeted radiation therapy that works on neuroendocrine tumor cells.

This article explains what your Ki-67 score means and how it affects your Lu-177 DOTATATE eligibility, including what to do when the answer is unclear.

What Is Ki-67 and How Is It Measured?

Ki-67 is a protein found in cells that are actively dividing. When a pathologist examines your tumor biopsy, they stain the tissue and count what percentage of cells show Ki-67. This percentage is called the Ki-67 index or Ki-67 proliferation index.

According to the National Cancer Institute, the Ki-67 proliferation index estimates how fast tumor cells are growing and dividing. A low number means the tumor is slow-growing. A higher number means more cells are dividing - and the tumor is likely growing faster.

The result is reported as a percentage - for example, Ki-67: 4% or Ki-67: 28%. A tissue biopsy taken during diagnosis or surgery provides this measurement. Ki-67 can sometimes differ between the primary tumor and a metastatic site, so ask your doctor whether grades were consistent if you have had biopsies from more than one location.

How WHO Grade Is Assigned in GEP-NETs

The World Health Organization (WHO) grades GEP-NETs using Ki-67 as the primary measure. The 2019 WHO classification - the current international standard - divides neuroendocrine neoplasms of the digestive system into grades and categories based on Ki-67 index and how the tumor cells look under the microscope.

The Neuroendocrine Tumor Research Foundation (NETRF) notes that grade reflects how fast the tumor is likely to grow. This is different from stage - stage tells you where the cancer has spread, while grade tells you how fast it may grow. Both matter for treatment planning.

The main grade categories for well-differentiated GEP-NETs are:

  • Grade 1 (G1): Ki-67 under 3%. Slow-growing. Often called low-grade.
  • Grade 2 (G2): Ki-67 between 3% and 20%. Intermediate growth rate.
  • Grade 3 (G3) NET: Ki-67 above 20%. Faster-growing, but still well-differentiated - meaning the cells still look similar to normal tissue under the microscope.

Neuroendocrine carcinoma (NEC) is a separate category. NEC is poorly differentiated. The cells look very abnormal, and Ki-67 is typically very high. NEC behaves differently from a well-differentiated G3 NET - and treatment is quite different as a result.

The distinction between a G3 NET and a NEC matters for PRRT eligibility. Both can have Ki-67 above 20%, which is why pathologists sometimes use additional tests beyond Ki-67 alone to make the final diagnosis.

How Do Ki-67 Grades Compare for Lu-177 DOTATATE Eligibility?

WHO grading of GEP-NETs and typical Lu-177 DOTATATE (PRRT) eligibility by Ki-67 category. Final eligibility depends on DOTATATE-PET uptake, kidney function, and other clinical factors reviewed by your care team.
WHO Grade Ki-67 Range Differentiation PRRT Eligibility Status
G1 (Low Grade) Under 3% Well-differentiated Generally eligible if DOTATATE-PET positive; timing depends on pace of progression
G2 (Intermediate) 3% to 20% Well-differentiated Generally eligible if DOTATATE-PET positive; NETTER-2 trial data supports PRRT in higher G2 range
G3 NET Above 20% (well-differentiated) Well-differentiated Assessed case by case; strong DOTATATE-PET uptake is key; trial data supports selected cases with Ki-67 up to 55%
NEC (Carcinoma) Variable; typically very high Poorly differentiated Typically not eligible; DOTATATE-PET usually shows poor uptake; chemotherapy is the standard first approach

Sources: WHO 2019 classification via NETRF; NETTER-2 trial summary via PubMed Central. Eligibility also depends on DOTATATE-PET uptake, kidney function, and other clinical factors.

G1 and G2 GEP-NETs make up most PRRT-eligible patients based on current trial evidence and regulatory approval. G3 NETs are an emerging area, with growing evidence supporting eligibility in selected cases. NEC typically does not respond to PRRT because the cells rarely express somatostatin receptors at a level adequate for treatment to work.

G1 and G2 GEP-NETs: The Clearest Candidates

The strongest evidence for lutetium Lu-177 dotatate comes from patients with G1 and G2 GEP-NETs. The NETTER-1 phase III trial, which led to FDA approval of Lutathera in January 2018, enrolled patients with progressive, well-differentiated, somatostatin receptor-positive midgut NETs - predominantly G1 and G2 tumors.

For these patients, PRRT typically comes after a somatostatin analogue - such as octreotide or lanreotide - has been tried and the tumor has grown despite that therapy. If your DOTATATE-PET scan shows strong uptake across lesions, and your kidney function and blood counts are adequate, a nuclear-medicine team will likely review you as a PRRT candidate.

One important point: having a G1 NET does not automatically mean you need PRRT now. Some G1 tumors grow slowly enough that continuing somatostatin analogue therapy and monitoring remains the right approach before moving to PRRT. The decision depends on growth rate, symptom burden, and other clinical factors. Our article on Grade 1 NET and PRRT: when Lu-177 DOTATATE can wait covers the timing question in detail.

Grade 3 GEP-NETs: An Evolving Picture

For years, G3 tumors with Ki-67 above 20% were generally considered inappropriate for PRRT. The concern was that higher-grade tumors would have lost enough somatostatin receptor expression to make PRRT ineffective.

That view has changed. Well-differentiated G3 NETs - where Ki-67 is elevated but the cells still look NET-like under the microscope - often keep meaningful somatostatin receptor expression. If a DOTATATE-PET scan shows strong uptake, an experienced team may recommend PRRT.

The NETTER-2 trial studied lutetium Lu-177 dotatate as a first-line strategy in patients with high G2 (Ki-67 10-20%) and G3 (Ki-67 20-55%) GEP-NETs. Evidence from this trial has expanded the eligibility discussion for patients in the upper Ki-67 range. A review of current PRRT evidence published via PubMed Central showed that PRRT is being used more often across G1 and G2 disease and in selected higher-grade tumors.

This does not mean every G3 NET should get PRRT. A Ki-67 of 25% in a well-differentiated pancreatic NET with strong DOTATATE-PET uptake is very different from a Ki-67 of 70% in a poorly differentiated carcinoma with no PET uptake. The pathology and the imaging both need review by a team with high volume NET experience.

For a detailed look at this topic, see our article on PRRT for high-grade GEP-NETs: is Lu-177 DOTATATE still an option?

When NEC Typically Rules Out PRRT

Poorly differentiated neuroendocrine carcinoma (NEC) is a separate disease from a well-differentiated NET. NEC cells have usually lost the surface proteins that PRRT targets. When a DOTATATE-PET scan shows little or no uptake across tumor lesions, PRRT is not appropriate.

In this situation, chemotherapy - typically platinum-based combinations - is the standard first approach rather than radioligand therapy. A multidisciplinary team review and a second pathology opinion from a center with high NET volume are especially important when the diagnosis falls at the boundary between a G3 NET and a NEC. The biological behavior of these two subtypes is different enough that getting the diagnosis right is itself a treatment decision.

Ki-67 Is One Piece of the Eligibility Picture

Even if your Ki-67 grade falls in a favorable range, several other factors are reviewed before a team will confirm PRRT eligibility. According to the National Cancer Institute treatment summary for gastrointestinal neuroendocrine tumors, tumor grade, receptor expression, prior therapy, and organ function are weighed together in NET treatment planning.

The key factors reviewed alongside Ki-67 include:

  • DOTATATE-PET scan results: Tumor uptake must be sufficiently strong across the lesions being targeted. A common reference point is uptake at least as high as normal liver uptake on imaging (sometimes called Krenning score 3 or 4).
  • Kidney function: The kidneys absorb some radiation during PRRT. Patients with significantly reduced kidney function need careful assessment before treatment can proceed.
  • Bone marrow reserve: Blood counts and prior treatment history are reviewed to confirm the bone marrow can tolerate PRRT. Prior heavy chemotherapy may affect this.
  • Liver tumor burden: Very extensive liver involvement requires additional assessment before a PRRT plan is finalized.
  • Overall performance status: How well you are functioning day-to-day is part of the eligibility review at most PRRT centers.

A single Ki-67 result cannot confirm or rule out eligibility on its own. A full case review - including current imaging, recent bloodwork, and treatment history - is needed before any recommendation can be made.

What If Your Case Falls in a Gray Zone?

Ki-67 scores near grade boundaries can make eligibility genuinely uncertain. A result of 19% sits just inside G2. A result of 22% in a well-differentiated tumor may behave more like a G2 than an aggressive carcinoma. In these situations, how the cells look on the pathology slide matters as much as the number itself.

It is reasonable - and often advisable - to have your pathology and DOTATATE-PET reviewed by a second team with specific GEP-NET experience before you commit to a treatment plan. If you want that review done remotely before traveling, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you and what alternatives exist if not. Their team reviews biopsy reports, pathology findings, and imaging to clarify eligibility before you make a decision about next steps.

Our guide on how to get a PRRT second opinion before travelling to India walks through exactly what documents to gather and how a remote eligibility review typically works for GEP-NET patients.

When to Talk to Your Doctor

Ask your oncologist what Ki-67 grade was found on your biopsy if it has not been clearly explained to you. Ask whether a Ga-68 DOTATATE-PET scan has been done or is appropriate for your case. If your disease has grown despite somatostatin analogues, ask whether PRRT belongs in your next-steps discussion. If your Ki-67 sits near the G2-G3 boundary, ask whether a second pathology review is worthwhile before a treatment decision is made.

You can also send your scans and pathology report for a remote eligibility review via the contact form at Lutetium Therapy. If lutetium Lu-177 dotatate is not the right fit for your case, the team can discuss what alternatives may be worth exploring.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What Ki-67 level qualifies for Lu-177 DOTATATE therapy?

There is no single fixed cut-off. G1 (Ki-67 under 3%) and G2 (Ki-67 3-20%) tumors that are somatostatin receptor-positive on DOTATATE-PET are generally considered eligible for PRRT, based largely on the NETTER-1 trial. Evidence from the NETTER-2 trial suggests eligibility may extend to well-differentiated G3 tumors with Ki-67 up to 55% in selected cases, depending on DOTATATE-PET uptake and other clinical factors. Ki-67 is always reviewed alongside imaging, kidney function, and overall health - not as a stand-alone number.

Can people with Grade 3 GEP-NETs receive PRRT?

Well-differentiated G3 NETs may be eligible for PRRT if they show adequate somatostatin receptor uptake on a DOTATATE-PET scan. Poorly differentiated neuroendocrine carcinoma (NEC), which can also have Ki-67 above 20%, typically does not respond to PRRT because those cells rarely express somatostatin receptors strongly enough. A pathologist needs to distinguish between a G3 NET and a NEC - using cell morphology and sometimes additional testing - before PRRT eligibility can be properly assessed.

What is the difference between a G3 NET and neuroendocrine carcinoma (NEC)?

Both a G3 NET and a NEC can have Ki-67 above 20%, which makes them easy to confuse. The key difference is differentiation. A G3 NET is well-differentiated: the cells still look similar to normal tissue under the microscope and often express somatostatin receptors. A NEC is poorly differentiated: the cells look very abnormal and have usually lost somatostatin receptor expression. The distinction matters greatly because PRRT works through somatostatin receptors and is generally not appropriate for NEC. Pathologists sometimes need additional staining or molecular testing to make this call.

Is Ki-67 the only test used to determine PRRT eligibility?

No. Ki-67 grade is one of several factors. A Ga-68 DOTATATE-PET scan is required to confirm that tumor lesions express somatostatin receptors at a level adequate for PRRT to work. Kidney function, bone marrow reserve (blood counts), liver tumor burden, and overall performance status are also reviewed before treatment is approved. Some patients have favorable Ki-67 grades but are not PRRT candidates because their DOTATATE-PET uptake is insufficient or their kidney function is too reduced.

My Ki-67 result is 18%. Am I likely eligible for PRRT?

A Ki-67 of 18% places you in the upper G2 range, which is generally considered eligible for PRRT if your DOTATATE-PET shows strong uptake and your kidney function and blood counts are adequate. However, eligibility is confirmed through a full clinical review - not by Ki-67 alone. A nuclear-medicine or NET specialist team will look at your imaging, bloodwork, treatment history, and overall health before making a recommendation. If you want an independent review before traveling for treatment, a remote second opinion is available.

Can Ki-67 change between biopsies?

Yes. Ki-67 can vary between the primary tumor site and metastatic lesions, and it can also change over time as the disease evolves or after prior treatments. A biopsy from an accessible metastatic lesion may give a more current picture of tumor behavior than the original biopsy taken years earlier. If your treatment team is making a decision about PRRT eligibility based on an older Ki-67 result, it is worth asking whether a more recent biopsy sample is available or appropriate.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Ki-67 Grade and GEP-NET Lu-177 DOTATATE Eligibility | lutetium-therapy